SCHEMBL6442604

SCHEMBL6442604

CCc1ccc(C(O)c2cc(Br)ccc2OC)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
ADRA2A P08913 1/20 0.37
ADRA1A P35348 1/20 0.37
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37
PPARA Q07869 1/20 0.37
OPRK1 P41145 1/20 0.37
TSHR P16473 1/20 0.37
GLA P06280 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TUBB1 Q9H4B7 2/20 0.36
TOP2A P11388 1/20 0.36
TOP2B Q02880 1/20 0.36
ALOX5 P09917 1/20 0.36
STAT3 P40763 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5752891 0.88 HPGD (0.43) LMNAADRA2AADRA1APPARGPPARD
SCHEMBL12291880 0.81 SMN1; SMN2 (0.46) LMNATSHRSMN1; SMN2
SCHEMBL1682164 0.80 TDP1 (0.44) LMNASMN1; SMN2
SCHEMBL13761466 0.79 ADRB2 (0.45) LMNAADRA2AADRA1A
SCHEMBL12290810 0.79 MAPT (0.37) LMNAADRA2ATSHRSMN1; SMN2
SCHEMBL12291535 0.78 ADRB2 (0.38) LMNATSHRSMN1; SMN2
SCHEMBL21362510 0.78 OPRK1 (0.38) OPRK1SMN1; SMN2TUBB1TOP2ATOP2B
SCHEMBL20157890 0.77 OPRK1 (0.35) OPRK1TUBB1TOP2ATOP2B
SCHEMBL15119669 0.77 TUBB1 (0.38) LMNAPPARGPPARDPPARATSHR
SCHEMBL20140072 0.76 KMT2A (0.40) LMNAADRA2AADRA1APPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936590-B2 C-aryl glucoside SGLT2 inhibitors and method BRISTOL MYERS SQUIBB COMPANY (US) 2005-08-30 US disclosed
EP-1224195-B1 C-ARYL GLUCOSIDE SGLT2 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2005-05-18 EP disclosed
US-20030114390-A1 C-aryl glucoside SGLT2 inhibitors and method ASTRAZENECA AB (SE) 2003-06-19 US disclosed
EP-1224195-A1 C-ARYL GLUCOSIDE SGLT2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-07-24 EP disclosed
US-6414126-B1 ANTIDIABETIC, ANTIOBESITY, ANTILIPEMIC, ANTIATHEROSCLEROTIC, ANTICOAGULANT, AND HYPOTENSIVE AGENTS; MARKUSH ENCOMPASSING DAPAGLIFOZIN AND DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY 2002-07-02 US disclosed
WO-2001027128-A1 C-ARYL GLUCOSIDE SGLT2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114390-A1 C-aryl glucoside SGLT2 inhibitors and method SLC5A2, SLC5A1, UGGT1 LMNA 3250/4885ADRA2A 871/4885ADRA1A 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.